Preventing Recurrent Clostridioides difficile Infections with Fecal Microbiota-Based Therapies : Episode 15
Safety of Fecal Microbiota Options and Transfer of Food-Borne Allergens
The panel provides insights on common adverse effects associated with fecal microbiota transplantation and analyzes the possibility of FMT products carrying pathogens or food-borne allergens.
Video Player is loading.
Video content above is prompted by the following:
- What are the common adverse effects associated with FMT?
- Since these products are made from human fecal matter, would there be a concern about them carrying pathogens or the transfer of food-borne allergens?
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Recent Videos
Oral Vancomycin "Tail" Offers No Added Benefit for CDI Prophylaxis
Fidaxomicin Use Remains Flat Despite Guideline Change for C difficile Treatment
Advancing C diff Management: Fidaxomicin, Microbiome Therapies, and Stewardship
Reviewing Real-World Safety and Efficacy Data on C difficile Therapy Rebyota
Colonoscopic Administration of Rebyota Shows Effectiveness for Preventing Recurrent C difficile Infection
Microbiota-Based Therapy Improves Mental Quality of Life in rCDI Trial
Education and Advocacy in DC: The PLF C Diff Summit and Lobby Day
Targeting C difficile with Oxygen-Based Therapy
Targeting the C Diff Pathogen and Its Immune-Suppressing Toxins
mRNA Vaccine Shows Potential for C difficile Infections
Related Content
